Prior approval opinions of independent directors on matters related to the fifth meeting of the third board of directors
Independent directors’ opinions on matters related to the fifth meeting of the third board of directors
Prior approval of
In accordance with the rules for independent directors of listed companies, the Listing Rules of GEM stocks of Shenzhen Stock Exchange, the self regulatory guidelines for listed companies of Shenzhen Stock Exchange No. 2 – standardized operation of GEM listed companies and other relevant regulations of the CSRC, as well as the relevant provisions of the Bgi Genomics Co.Ltd(300676) articles of Association and Bgi Genomics Co.Ltd(300676) independent director system, As an independent director of Bgi Genomics Co.Ltd(300676) (hereinafter referred to as the company), we have conducted a prior review of the relevant proposals to be considered at the fifth meeting of the third board of directors of the company, and now express the following prior approval opinions:
1、 Prior approval opinions on the prediction of daily connected transactions in 2022
1. The expected events of the company’s daily related party transactions in 2022 are generated from the company’s daily business activities, which meets the actual needs of the company’s business development. The transaction price is determined according to the principles of market price and cost plus. The pricing is fair and reasonable, and there is no situation that damages the interests of the company and shareholders, especially the interests of minority shareholders.
2. Before submitting the above proposal to the board of directors for deliberation, the company has communicated with us about the related party transaction in advance, the relevant contents of relevant matters and materials have been approved by us, and the related party transaction complies with the specified deliberation procedures.
We unanimously agreed to submit the proposal on the prediction of daily connected transactions in 2022 to the fifth meeting of the third board of directors of the company for deliberation.
2、 Prior approval opinions on donation and related party transactions to Shenzhen mammoth Public Welfare Foundation
The company’s donation to mammoth foundation aims to promote the scientific research and clinical application of gene testing technology in the prevention of birth defects, tumor prevention and control, infection prevention and control, and combating covid-19 epidemic; Improve the research level of life sciences; Promote the development of social science popularization and public welfare undertakings. This related party transaction does not harm the interests of the company and shareholders, especially the interests of minority shareholders. Before the proposal is submitted to the board of directors for deliberation, it has been submitted to us for review and approval.
Prior approval opinions of independent directors on matters related to the fifth meeting of the third board of directors
We unanimously agreed to submit the proposal on donation and related party transactions to Shenzhen mammoth public welfare foundation to the fifth meeting of the third board of directors of the company for deliberation.
Independent directors: Cao ya, Du Lan, Wu Yuhui January 19, 2022
